Granules India Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Granules India wird ein jährliches Gewinn- und Umsatzwachstum von 23.5% bzw. 12% prognostiziert. Der Gewinn pro Aktie wird voraussichtlich wachsen um 23.4% pro Jahr. Die Eigenkapitalrendite wird in 3 Jahren voraussichtlich 17% betragen.

Wichtige Informationen

22.9%

Wachstumsrate der Gewinne

23.7%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	17.1%
Wachstumsrate der Einnahmen	11.9%
Zukünftige Eigenkapitalrendite	17.0%
Analystenabdeckung	Good
Zuletzt aktualisiert	11 Jul 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Jan 26

Recent updates

Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50

Jun 19

Investors Holding Back On Granules India Limited (NSE:GRANULES)

Apr 08

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Jan 26

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Dec 21

Here's Why I Think Granules India (NSE:GRANULES) Is An Interesting Stock

Aug 18

Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.25

Aug 03

Is Granules India (NSE:GRANULES) Using Too Much Debt?

Jun 11

Why Granules India Limited (NSE:GRANULES) Is A Dividend Rockstar

May 02

Does This Valuation Of Granules India Limited (NSE:GRANULES) Imply Investors Are Overpaying?

Mar 26

What Kind Of Investors Own Most Of Granules India Limited (NSE:GRANULES)?

Mar 14

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Mar 01

Granules India Limited (NSE:GRANULES) Stock Has Shown Weakness Lately But Financials Look Strong: Should Prospective Shareholders Make The Leap?

Feb 16

Why You Might Be Interested In Granules India Limited (NSE:GRANULES) For Its Upcoming Dividend

Feb 03

Analysts Have Made A Financial Statement On Granules India Limited's (NSE:GRANULES) Third-Quarter Report

Jan 30

Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching

Jan 20

Gewinn- und Umsatzwachstumsprognosen

NSEI:GRANULES - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (INR Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
3/31/2027	63,183	7,973	3,461	9,561	1
3/31/2026	58,460	7,107	3,424	8,449	5
3/31/2025	50,716	5,716	1,475	7,659	6
3/31/2024	45,064	4,053	588	4,394	N/A
12/31/2023	45,261	3,953	N/A	N/A	N/A
9/30/2023	45,166	3,939	-346	3,769	N/A
6/30/2023	44,779	4,369	N/A	N/A	N/A
3/31/2023	45,119	5,166	3,281	7,387	N/A
12/31/2022	43,464	5,080	N/A	N/A	N/A
9/30/2022	41,970	4,845	1,545	4,970	N/A
6/30/2022	39,346	4,201	N/A	N/A	N/A
3/31/2022	37,649	4,128	-657	3,321	N/A
12/31/2021	35,343	4,293	N/A	N/A	N/A
9/30/2021	33,820	4,753	735	4,714	N/A
6/30/2021	33,518	5,582	N/A	N/A	N/A
3/31/2021	32,375	5,495	1,611	4,325	N/A
12/31/2020	30,381	5,142	N/A	N/A	N/A
9/30/2020	28,976	4,314	2,723	4,459	N/A
6/30/2020	27,390	3,636	N/A	N/A	N/A
3/31/2020	25,986	3,354	2,917	4,762	N/A
12/31/2019	26,121	3,071	N/A	N/A	N/A
9/30/2019	25,399	3,034	1,551	3,714	N/A
6/30/2019	24,212	2,679	N/A	N/A	N/A
3/31/2019	22,792	2,364	-172	2,622	N/A
12/31/2018	21,697	1,928	N/A	N/A	N/A
9/30/2018	19,487	1,675	N/A	N/A	N/A
6/30/2018	17,603	1,476	N/A	N/A	N/A
3/31/2018	16,846	1,326	-4,471	-7	N/A
12/31/2017	15,361	1,578	N/A	N/A	N/A
9/30/2017	14,785	1,619	N/A	N/A	N/A
6/30/2017	14,456	1,624	N/A	N/A	N/A
3/31/2017	14,106	1,645	N/A	1,882	N/A
12/31/2016	14,971	1,473	N/A	N/A	N/A
9/30/2016	14,626	1,374	N/A	N/A	N/A
6/30/2016	14,524	1,289	N/A	N/A	N/A
3/31/2016	13,572	1,230	N/A	1,514	N/A
12/31/2015	14,147	1,077	N/A	N/A	N/A
9/30/2015	13,895	1,041	N/A	N/A	N/A
6/30/2015	13,307	952	N/A	N/A	N/A
3/31/2015	12,937	909	N/A	1,503	N/A
12/31/2014	12,573	921	N/A	N/A	N/A
9/30/2014	12,217	904	N/A	N/A	N/A
6/30/2014	11,786	834	N/A	N/A	N/A
3/31/2014	10,973	752	N/A	1,079	N/A
12/31/2013	9,837	640	N/A	N/A	N/A
9/30/2013	8,948	480	N/A	N/A	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: GRANULESDas prognostizierte Gewinnwachstum (23.5% pro Jahr) liegt über der Sparquote (6.7%).

Ertrag vs. Markt: GRANULESDie Erträge des Unternehmens (23.5% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (16% pro Jahr).

Hohe Wachstumserträge: GRANULESEs wird erwartet, dass die Erträge des Unternehmens in den nächsten 3 Jahren erheblich steigen werden.

Einnahmen vs. Markt: GRANULESDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich schneller wachsen als der Markt Indian (9.6% pro Jahr).

Hohe Wachstumseinnahmen: GRANULESDie Einnahmen des Unternehmens (12% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: GRANULESDie Eigenkapitalrendite des Unternehmens wird in 3 Jahren voraussichtlich niedrig sein (17%).

Granules India Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Price target increased by 8.1% to ₹375

Price target increased to ₹338

Price target decreased to ₹319

Price target decreased to ₹330

Price target decreased to ₹388

Recent updates

Granules India's (NSE:GRANULES) Dividend Will Be ₹1.50

Investor sentiment improves as stock rises 15%

Dividend of ₹1.50 announced

Granules India Limited, Annual General Meeting, Aug 06, 2024

Full year 2024 earnings: EPS and revenues miss analyst expectations

Granules India Limited Recommends Final Dividend for the Financial Year 2023-24, Payable on July 30, 2024

Granules India Limited to Report Q4, 2024 Results on May 15, 2024

High number of new directors

Investors Holding Back On Granules India Limited (NSE:GRANULES)

Granules India Limited Appoints Atul Dhavle as Chief Human Resources Officer

Granules India Limited Announces That J. Shravan Reddy Shall Cease to Be Senior Vice President & Head- API Manufacturing

Granules India Limited Just Missed Revenue By 6.4%: Here's What Analysts Think Will Happen Next

Third quarter 2024 earnings released: EPS: ₹5.18 (vs ₹5.11 in 3Q 2023)

Granules India Limited to Report Q3, 2024 Results on Jan 23, 2024

Many Still Looking Away From Granules India Limited (NSE:GRANULES)

Granules India Limited Receives ANDA Approval for Pantoprazole Sodium Delayed-Release Tablets

Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet

Price target increased by 8.1% to ₹375

Second quarter 2024 earnings released: EPS: ₹4.22 (vs ₹5.85 in 2Q 2023)

Granules India Limited to Report Q2, 2024 Results on Nov 09, 2023

A Look At The Fair Value Of Granules India Limited (NSE:GRANULES)

Granules India Limited Receives ANDA Approval for Esomeprazole Magnesium Delayed-Release Capsules

Granules India Limited Approves Final Dividend for the Fy 2022-23

Granules India Limited Receives US FDA Approval for the ANDA Files for Metoprolol Succinate ER Tablets Registered Office

Granules India Limited to Report Q1, 2024 Results on Aug 09, 2023

Upcoming dividend of ₹1.50 per share at 0.5% yield

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Granules India Limited Announces Approval for the Store Brand OTC Equivalent of Advil®? Dual Action Tablets Registered Office

Granules India Limited Receives ANDA Approval for Venlafaxine ER Capsules

Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?

Granules India Limited, Annual General Meeting, Aug 10, 2023

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Should You Be Adding Granules India (NSE:GRANULES) To Your Watchlist Today?

Third quarter 2023 earnings: EPS misses analyst expectations

Granules India (NSE:GRANULES) Has A Pretty Healthy Balance Sheet

Granules India Limited to Report Q3, 2023 Results on Jan 24, 2023

Granules India Limited Announces Resignation of Sandip Neogi as Chief Financial Officer (Cfo)

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Granules India Limited to Report Q2, 2023 Results on Oct 20, 2022

Does Granules India (NSE:GRANULES) Have A Healthy Balance Sheet?

Granules India Limited Receives Approval for Abbreviated New Drug Application from US Food & Drug Administration

Estimating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)

Price target increased to ₹338

Granules India Limited (BSE:532482) announces an Equity Buyback for 6,250,000 shares, representing 2.52% for INR 2,500 million.

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Granules India Limited to Report Q1, 2023 Results on Aug 09, 2022

Granules India Limited Approves Final Dividend for the Financial Year 2021-22

Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.75

Upcoming dividend of ₹0.75 per share

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Investor sentiment improved over the past week

Is Granules India (NSE:GRANULES) A Risky Investment?

Now 21% undervalued after recent price drop

Price target decreased to ₹319

Granules India (NSE:GRANULES) Will Pay A Dividend Of ₹0.75

Granules India Limited, Annual General Meeting, Jul 27, 2022

Price target decreased to ₹330

Granules India Recommends Final Dividend for the Financial Year 2021-22

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Estimating The Fair Value Of Granules India Limited (NSE:GRANULES)

Granules India (NSE:GRANULES) Is Due To Pay A Dividend Of ₹0.25

Granules India Limited Declares Third Interim Dividend for the Financial Year 2021-22

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Calculating The Intrinsic Value Of Granules India Limited (NSE:GRANULES)

Now 21% undervalued after recent price drop

Here's Why We Think Granules India (NSE:GRANULES) Is Well Worth Watching

These 4 Measures Indicate That Granules India (NSE:GRANULES) Is Using Debt Reasonably Well

Insufficient new directors

Second quarter 2022 earnings released: EPS ₹3.26 (vs ₹6.60 in 2Q 2021)